Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore

Paris, France, 5th May 2017 – Pharmaleads, an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, today announced that a poster presentation on its Dual ENKephalinase Inhibitor (DENKI) PL265 has been accepted for presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting which is being held from May 7th – 11th, 2017 in Baltimore, US.

Pharmaleads is a world leader in the understanding of the role of enkephalins in the management of local pain relief. Enkephalins are degraded by two enzymes, the enkephalinases NEP and APN, from the zinc-metallopeptidase family. Pharmaleads medicinal chemistry expertise has allowed the Company to develop drugs called DENKIs that are able to improve pain management by increasing the local concentrations of enkephalins, inhibiting the two enzymes responsible for their degradation.

PL265, one of the two drugs in clinical development at Pharmaleads, is being developed as eye-drops for ophthalmic pain/ dry eye syndrome.

The poster session details are:

Poster No.:   B0059
Program Number: 5172
Poster Title: Dual enkephalinase inhibitor (DENKI) PL265: a novel topical treatment for ocular pain?
Presentation Time:  Thursday, May 11, 8:30 AM -10:130 AM
Session: Toxicology; hypoxia; ischemia; oxidative stress; corneal disease

Download Full Version 

Press releases - Latest posts

Discover our publications